Eli Lilly (NYSE: LLY) stock is on a tear. Buoyed by an investor frenzy over GLP-1 weight-loss drugs -- Lilly's own Zepbound in particular -- shares of the Indianapolis-based drugmaker are up 148% over the last 52 weeks, and have been setting new all-time highs on an almost daily basis. Think they can't possibly go higher?

Think again.

On Friday, Bank of America analysts laid out their case for why they think Lilly's run is still only in its early stages, and why this buy-rated stock currently priced at $782 might hit $1,000 a share within the next year (a 28% jump).

Continue reading

Source Fool.com